Date: 2017-05-22
Type of information: Collaboration agreement
Compound:
Company: PCI Biotech (Norway) RXi Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D - research
Action mechanism:
Disease:
Details:
- • On May 22, 2017, PCI Biotech and RXi Pharmaceuticals announced that they are extending their preclinical research collaboration initiated April 7, 2015. This extension will focus on immuno-oncology and is supported by a new preclinical research collaboration agreement that reflect RXi’s recently completed acquisition of MirImmune and PCI Biotech’s focus in oncology. The preclinical research collaboration will evaluate technology compatibility and PCI Biotech's fimaNAc and RXi’s innovative RNAi based compounds synergy. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
Financial terms:
Latest news:
Is general: Yes
